Email This Release
Genzyme Presents Second Phase III Study of Once-daily Oral AUBAGIO® (teriflunomide) Confirming Significant Impact on Disability
*
marks required fields
Recipient Name:
*
Recipient Email:
Message:
*
Enter security words:
Terms of Use
|
© 2024 Business Wire